<DOC>
	<DOCNO>NCT00411372</DOCNO>
	<brief_summary>This study last approximately 8 week involve 4 visit . The study carry validate shortness breath questionnaire</brief_summary>
	<brief_title>Shortness Of Breath Questionnaire Validation Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Diagnosis COPD Women pregnant lactating . Subjects primary diagnosis asthma . ( Subjects prior history asthma eligible COPD currently primary diagnosis ) Has respiratory disorder COPD ( e.g. , bronchiectasis , sarcoidosis , active tuberculosis , lung fibrosis ) , include subject diagnosis alpha1antitrypsin deficiency . Subjects lung volume reduction surgery lung transplant within previous 12 month . Chest Xray ( posterioranterior ) CT scan reveals evidence clinically significant abnormality believe due presence COPD . A chest Xray must take subject one within 12 month Screening Visit . Subjects clinically significant cardiovascular ( include clinically significant ECG abnormality , CHF ) , neurological , psychiatric , renal , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled . Subjects carcinoma complete remission least 5 year . Carcinoma situ cervix , squamous cell carcinoma skin basal cell carcinoma would consider exclusion criterion subject consider cure less 5 year since diagnosis . Any adverse reaction include immediate delay hypersensitivity betaagonist , sympathomimetic drug , intranasal , inhale , oral corticosteroid include component formulation ( e.g . lactose milk protein ) . Initiation systemic betablocker medication time study . Systemic betablockers betablocker eye drop allow subject stable regimen least 30 day prior screen judge capable continue regimen discharge study . Subject continue prohibit medication , list Section 5.6.2 . Subject receive treatment longterm oxygen therapy ( LTOT ) , define inSection 5.6.2 . Use immunosuppressive medication time study . Immunotherapy treatment allergy allow study provide subject receive constant dose 30 day prior Screening Visit dose maintain study . Subjects medically unable withhold albuterol ipratropium 6 hour period require prior administration questionnaire spirometry study visit . An infection upper low respiratory tract require treatment antibiotic 14 day prior Screening Visit . Subjects require nocturnal positive pressure . Enrolled discontinuation pulmonary rehabilitation program within 30 day Visit 1 . Subjects enrol pulmonary rehabilitation program study start maintain participation program duration study . Use investigational drug within 30 day Visit 1 time study allow . Subjects unable comply study procedure . Study investigator , subinvestigators , study coordinator , employee participate investigator immediate family member aforementioned excluded participation study . Subjects history psychiatric disease , intellectual deficiency , poor motivation , substance abuse , ( include drug alcohol ) , condition , limit validity inform consent participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Questionnaire</keyword>
	<keyword>COPD</keyword>
	<keyword>Shortness Breath</keyword>
</DOC>